PRODUCT NAME

Rintatolimod 

(U.S. Tradename: Ampligen®)

Alferon N Injection®

Alferon N Injection®

Country: Argentina
CATEGORY

Ampligen (rintatolimod) sterile solution is indicated for the treatment of severely debilitated patients with chronic fatigue syndrome (cfs) who have been diagnosed for longer than one year.

Treatment of refractory or recurrent external condylomata acuminata

Treatment of patients who initially responded to recombinant interferon alfa, including pegylated recombinant alpha interferon, but that the treatment subsequently failed due to the presence of neutralizing antibodies or the intolerance of patients to these treatments

COMMERCIAL STATUS

Approved. Launch pending FDA export authorization.

Approved. Launch pending FDA manufacturing approval.

Approved. Launch pending FDA manufacturing approval.

PRODUCT NAME

Rintatolimod 

(U.S. Tradename: Ampligen®)

CATEGORY

Ampligen (rintatolimod) sterile solution is indicated for the treatment of severely debilitated patients with chronic fatigue syndrome (cfs) who have been diagnosed for longer than one year.

COMMERCIAL STATUS

Approved. Launch pending FDA export authorization.

Alferon N Injection®

CATEGORY

Treatment of refractory or recurrent external condylomata acuminata

COMMERCIAL STATUS

Approved. Launch pending FDA manufacturing approval.

Alferon N Injection®

Country: Argentina
CATEGORY

Treatment of patients who initially responded to recombinant interferon alfa, including pegylated recombinant alpha interferon, but that the treatment subsequently failed due to the presence of neutralizing antibodies or the intolerance of patients to these treatments

COMMERCIAL STATUS

Approved. Launch pending FDA manufacturing approval.

PRODUCT NAME

Alferon N Injection®

Country: USA
CATEGORY

Intralesional treatment of refractory or recurring external condylomata acuminata

COMMERCIAL STATUS

Sales anticipated to resume upon successful pre-approval inspection and supplemental approval by FDA

Questions Or Comments?

If you have any additional questions or comments click below.